Our meta-analysis highlights the significant therapeutic efficacy of low-dose, long-term rituximab (rituximab) regimens in the treatment of PLA2R-associated primary MGN. The gene discussed is PLA2R1; the disease is idiopathic membranous glomerulonephritis.